Oncolytics Biotech reported that in its GOBLET Cohort 4 study of pelareorep plus atezolizumab in third-line metastatic squamous cell anal carcinoma, four of 14 evaluable patients achieved objective responses, yielding an ORR of approximately 29%. This included two complete responses and two partial responses, a nearly threefold improvement over the historical benchmark ORR of around 10% in this refractory population. The cohort enrolled patients who had progressed after multiple prior systemic therapies, representing an area with no FDA-approved third-line treatment options.

The median duration of response for responders in Cohort 4 is approximately 17 months (67 weeks), indicating both depth and durability of clinical benefit in a heavily pretreated group. By comparison, historical third-line studies report limited durability, with responses often lasting less than six months. In the second-line setting, pelareorep plus atezolizumab achieved a 30% ORR and a median DOR of 15.5 months versus a 13.8% ORR and 9.5-month DOR for the current standard of care therapy, underscoring the regimen’s potential to set a new efficacy benchmark.

Encouraged by these data, Oncolytics plans to seek a Type C meeting with the FDA in Q1 2026 to align on a registration-directed study in third-line anal cancer. The company believes reproducing the 29% ORR and durable responses in a pivotal trial could support accelerated approval under FDA precedent for rare cancers without existing therapies. Oncolytics has already received positive feedback from key opinion leaders and preliminary FDA discussions, positioning the planned registration study to potentially address a significant unmet medical need.

Beyond anal cancer, pelareorep is advancing in multiple indications, including metastatic pancreatic and breast cancers, both of which hold Fast Track designations. The company is exploring combinations with chemotherapy and checkpoint inhibitors, and is actively pursuing partnerships to accelerate development and commercialization. With a precision medicine market forecast to expand from $138.7 billion in 2026 to $537.2 billion by 2035, Oncolytics is strategically positioned to leverage pelareorep’s novel mechanism of converting immunologically “cold” tumors “hot” and to capture value across gastrointestinal and solid tumor indications.